Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01123265 · ClinicalTrials.gov registry record

National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study

A clinical trial of Psoriatic Arthritis, sponsored by University of Rochester.

Completed
Registry status
22
Enrollment target
1
Study location

NCT01123265: Completed study of Psoriatic Arthritis, sponsored by University of Rochester.

NCT01123265 is a study of Psoriatic Arthritis that has completed, run by University of Rochester. The registered enrollment target is 22 participants, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01123265, a study of Psoriatic Arthritis, has completed, sponsored by University of Rochester.

COMPLETED
Registry status
22 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to determine whether DC-STAMP, a protein on the surface of osteoclast precursors (OCPs), can be used as a biologic marker in Psoriatic Arthritis (PsA). With this marker the investigators hope to learn more about how OCPs develop as well as find out if DC-STAMP predicts PsA severity and how well treatment works in PsA.

Primary Outcome

Determine whether DC-STAMP+ cells belong to the Th17 subset and also analyze the DC subsets for DC-STAMP expression.

Conditions Studied

Interventions

  • DRUG Methotrexate
  • DRUG Anti-TNF

Study Locations (1)

New York

  • University of Rochester - Rochester

Trial Details

FieldValue
Enrollment Target 22 participants
Start Date 2010-06
Est. Completion 2014-06
University of Rochester

636 total trials

What the finished NCT01123265 record still lists

NCT01123265 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 852-participant average among 48 other Psoriatic Arthritis trials with a reported enrollment target (97% lower).

The record links to 1 condition, with Psoriatic Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Methotrexate is the first listed.

NCT01123265 reports a single indexed study location in New York.

Frequently Asked Questions

What is clinical trial NCT01123265 about?

NCT01123265 is a clinical study titled "National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study". The purpose of this study is to determine whether DC-STAMP, a protein on the surface of osteoclast precursors (OCPs), can be used as a biologic marker in Psoriatic Arthritis (PsA). With this marker the investigators hope to learn more about how OCPs develop as well as find out if DC-STAMP predicts P...

What is the current status of trial NCT01123265?

This trial is currently completed. The enrollment target is 22 participants. The study started on 2010-06. Estimated completion is 2014-06.

What conditions does trial NCT01123265 study?

This clinical trial studies the following conditions: Psoriatic Arthritis.

What interventions are being tested in trial NCT01123265?

The interventions under investigation include: Methotrexate (DRUG), Anti-TNF (DRUG).

Who is sponsoring clinical trial NCT01123265?

This trial is sponsored by University of Rochester, which has 636 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01123265 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Psoriatic Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01123265's enrollment target sits among peer trials

22 45th of 48 higher than 4 of 48 other Psoriatic Arthritis trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Psoriatic Arthritis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02508038 · 22 participants · Phase 1

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

  • NCT03099356 · 22 participants · Phase 2

    Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer

  • NCT03676647 · 22 participants

    Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules

  • NCT04569591 · 22 participants · NA

    DDAVP for Pituitary Adenoma

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01123265, the US trial registry maintained by the National Library of Medicine. NCT01123265 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.